MML Investors Services
PRAX icon

MML Investors Services’s Praxis Precision Medicines PRAX Stock Holding History

MML Investors Services’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-639
Closed -$206K – 3306
2026
Q1 		$206K Sell
639
-225
-26% -$69.6K ﹤0.01% 2808
2025
Q4 		$255K Buy
+864
New +$161K ﹤0.01% 2739

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MML Investors Services's PRAX Position: Q2 2026 in Review

MML Investors Services sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 639 shares — an estimated $206K sold.

MML Investors Services first reported a position in PRAX in Q4 2025 and held it in 2 quarters. The position peaked at $255K in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • MML Investors Services reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
  • MML Investors Services sold 639 Praxis Precision Medicines shares in Q2 2026, an estimated $206K.
  • MML Investors Services first reported a position in Praxis Precision Medicines in Q4 2025 and held it in 2 quarters.
  • MML Investors Services's Praxis Precision Medicines position peaked at $255K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.